Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2/Neu Positive|HLA-A2 Positive Cells Present|Stage IV Breast Cancer|Stage IV Ovarian Cancer
Interventions: BIOLOGICAL: HER-2/neu Peptide Vaccine|OTHER: Laboratory Biomarker Analysis
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)